Nk Cell Therapy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda,

Nk Cell Therapy Pipeline constitutes 140+ key companies continuously working towards developing 160+ Nk Cell Therapy treatment therapies, analyzes DelveInsight.

Nk Cell Therapy Overview:

Natural Killer (NK) cells are a type of lymphocyte that plays a crucial role in the innate immune system, targeting tumors and virus-infected cells. They contain cytotoxic granules with proteins like perforins and granzymes, which induce apoptosis in target cells. NK cells originate from common lymphoid progenitor cells and mature in organs such as the bone marrow, spleen, and thymus before entering the bloodstream.

These cells can migrate into tissues and are activated by interleukins, allowing them to secrete cytokines and regulate immune responses. NK cells recognize self MHC class I molecules to develop self-tolerance and differentiate into tissue-specific subsets in organs like the liver and uterus.

Their function is controlled by a balance of activating and inhibitory receptors. NK cells are triggered when they detect abnormalities, such as reduced MHC class I expression or stress-induced ligands, which often occur during infections or cancerous transformations.

Request for a detailed insights report on Nk Cell Therapy pipeline insights @ https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Nk Cell Therapy Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nk Cell Therapy Therapeutics Market.

Key Takeaways from the Nk Cell Therapy Pipeline Report

DelveInsight's Nk Cell Therapy pipeline report depicts a robust space with 140+ active players working to develop 160+ pipeline therapies for Nk Cell Therapy treatment.
October 2024: ImmunityBio announced that the first patients have been dosed in an initial trial evaluating its CAR-NK cell therapy targeting CD-19 for the treatment of non-Hodgkin's lymphoma (NHL).

July 2024: Nkarta received FDA approval to initiate a clinical trial for its cell therapy candidate, NKX019, in patients with ANCA-associated vasculitis (AAV) and other autoimmune diseases.

May 2024: KGen Biotech's Safety Review Committee approved the progression of its cryopreserved autologous NK cell therapy, SNK01, into Phase II clinical trials.

May 2024: Fate Therapeutics announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be presented at the ASGCT 27th Annual Meeting.

April 2024: Sanofi advanced its NK cell engager candidate, SAR443579/IPH6101, to a Phase II trial for the treatment of various blood cancers.

April 2024: The FDA granted orphan drug designation to IGNK001 (Gengleucel), an investigational therapy for acute myeloid leukemia (AML).

Key Nk Cell Therapy companies such as Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and others are evaluating new drugs for Nk Cell Therapy to improve the treatment landscape.
Promising Nk Cell Therapy pipeline therapies in various stages of development include Bemarituzumab, Monalizumab, L1 t-haNK, M ceNK, DF6002, oNKord, KUR-501, and others.

Nk Cell Therapy Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Nk Cell Therapy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nk Cell Therapy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Nk Cell Therapy market.

Download our free sample page report on Nk Cell Therapy pipeline insights @ https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Nk Cell Therapy Emerging Drugs

Bemarituzumab: Amgen
Monalizumab: Innate Pharma
L1 t-haNK: ImmunityBio
M ceNK: ImmunityBio
DF6002: Dragonfly Therapeutics
oNKord: Glycostem Therapeutics
KUR-501: Athenex

Nk Cell Therapy Companies

Around 75 key companies are actively developing therapies for Nk Cell Therapy. Among them, Carsgen Therapeutics has a drug candidate in the most advanced stage, classified as Registered.

DelveInsight's report covers around 160+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Nk Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Nk Cell Therapy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Nk Cell Therapy Therapies and Key Companies: Nk Cell Therapy Clinical Trials and advancements @ https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Nk Cell Therapy Pipeline Therapeutic Assessment
• Nk Cell Therapy Assessment by Product Type
• Nk Cell Therapy By Stage
• Nk Cell Therapy Assessment by Route of Administration
• Nk Cell Therapy Assessment by Molecule Type

Download Nk Cell Therapy Sample report to know in detail about the Nk Cell Therapy treatment market @ Nk Cell Therapy Therapeutic Assessment @ https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Nk Cell Therapy Current Treatment Patterns
4. Nk Cell Therapy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Nk Cell Therapy Late-Stage Products (Phase-III)
7. Nk Cell Therapy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Nk Cell Therapy Discontinued Products
13. Nk Cell Therapy Product Profiles
14. Nk Cell Therapy Key Companies
15. Nk Cell Therapy Key Products
16. Dormant and Discontinued Products
17. Nk Cell Therapy Unmet Needs
18. Nk Cell Therapy Future Perspectives
19. Nk Cell Therapy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Nk Cell Therapy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.